Equities

Orgenesis Inc

Orgenesis Inc

Actions
  • Price (USD)1.25
  • Today's Change0.05 / 4.17%
  • Shares traded7.30k
  • 1 Year change-77.61%
  • Beta1.3247
Data delayed at least 15 minutes, as of Nov 13 2024 20:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

  • Revenue in USD (TTM)662.00k
  • Net income in USD-29.02m
  • Incorporated2008
  • Employees146.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Optimus Healthcare Services Inc1.89m-7.16m4.92m12.00------2.61-0.1744-0.17440.0454-0.18891.26--3.67157,291.70-477.28------85.93---379.51-----5.42----22.88---3.51------
Encision Inc6.56m-529.29k4.99m22.00--2.68--0.7599-0.045-0.0450.5560.15661.702.107.59298,337.30-13.69-3.03-19.50-4.1349.0051.25-8.06-1.891.01-8.890.1761---10.38-5.64-113.55---9.54--
Sharps Technology Inc0.00-8.21m5.05m3.00--0.5059-----10.88-10.880.005.550.00-------75.56---100.97----------0.6446--0.00-------112.12------
Dalrada Financial Corporation32.16m-21.34m5.06m0.00--0.5725--0.1573-0.2388-0.23880.35730.0911.098.863.37---75.10-80.63-239.06--30.1139.23-68.78-63.941.24-21.540.3452--54.35---43.94------
Bionoid Pharma Inc0.001.35m5.40m13.000.0882--3.99--1.131.130.00-0.1744-----------506.64--------------327.24---------31.55--26.01--
Predictive Oncology Inc1.75m-14.04m5.40m34.00--1.13--3.09-3.36-3.360.41580.71710.11081.454.2851,425.29-88.98-91.80-121.17-126.2960.2364.64-802.93-1,419.991.37--0.0634--18.244.7545.67--5.44--
ADM Tronics Unlimited Inc3.06m-472.80k5.41m7.00--5.30--1.77-0.007-0.0070.04530.01511.113.725.67---17.14-15.22-29.35-22.0942.8741.15-15.45-18.580.8954--0.3259---19.35-0.3572-810.74------
Aethlon Medical, Inc.0.00-11.50m5.66m14.00--0.6496-----3.87-3.870.000.62510.00----0.00-84.49-76.25-98.84-85.78-------2,246.87----0.00---100.00---1.43------
Agape ATP Corp1.38m-2.45m5.70m21.00--1.77--4.13-0.6396-0.63960.35990.83660.44648.2536.6665,621.91-78.78---111.56--64.23---176.47--4.66--0.0225---22.92---24.61------
Orgenesis Inc662.00k-29.02m5.96m146.00------9.01-8.68-8.680.2005-3.300.027278.295.384,534.25-122.18---1,312.10---101.06---4,489.28--0.0741-5.85-----98.53-50.94-271.82---17.71--
Kelyniam Global Inc517.70k-420.28k6.11m0.00--11.13--11.80-0.0253-0.02530.03120.01790.41357.044.38---33.57---41.79--18.86---81.18--1.26--0.6232---26.47---19.10------
Biomerica Inc5.51m-6.16m6.11m63.00--1.14--1.11-0.3663-0.36630.32740.31780.52232.633.6987,412.70-58.44-44.68-71.68-51.738.8114.11-111.89-63.822.09--0.00--1.420.810916.27---7.64--
Caduceus Software Systems Corp0.00-117.60k6.85m0.00---------0.0004-0.00040.00-0.00040.00-------402.19-11,090.31---------------76.88---------20,519.89------
Scientific Industries Inc10.45m-7.76m7.14m63.00--0.6114--0.6832-0.9231-0.92311.171.110.73431.139.08165,942.90-54.50---62.11--45.41---74.22--3.15--0.00--------------
Cutera Inc169.19m-148.97m7.15m430.00------0.0423-7.46-7.468.46-10.730.45722.083.86393,460.50-40.25-22.00-51.64-30.728.1847.63-88.05-27.242.17-31.342.05---15.865.47-97.76--85.87--
Neurometrix Inc3.77m-7.68m7.33m26.00--0.4568--1.95-4.59-4.592.167.860.19591.039.87144,914.20-39.90-23.24-42.63-27.2657.5659.17-203.71-48.8812.70--0.00---28.52-18.18-47.84--5.03--
Data as of Nov 13 2024. Currency figures normalised to Orgenesis Inc's reporting currency: US Dollar USD

Institutional shareholders

4.13%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202491.02k1.91%
Knoll Capital Management LPas of 30 Jun 202463.47k1.33%
Geode Capital Management LLCas of 30 Sep 202438.03k0.80%
XTX Markets LLCas of 30 Jun 20241.63k0.03%
Virtu Americas LLCas of 30 Jun 20241.21k0.03%
UBS Securities LLCas of 30 Jun 2024627.000.01%
Lord, Abbett & Co. LLCas of 30 Jun 2024444.000.01%
SSgA Funds Management, Inc.as of 30 Jun 2024351.000.01%
Tower Research Capital LLCas of 30 Jun 202463.000.00%
Simplex Trading LLCas of 30 Sep 202448.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.